Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 9/20 | 0.62 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.55 |
| ▸ | CDK2 | P24941 | 5/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.55 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.55 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.50 |
| ▸ | CDK9 | P50750 | 1/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.50 |
| ▸ | WNT3A | P56704 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18861503 | 1.00 | GLS (0.62) | GLSCDK5CDK2CCNE1CDK5R1 | |
| SCHEMBL18860812 | 1.00 | GLS (0.62) | GLSCDK5CDK2CCNE1CDK5R1 | |
| SCHEMBL18860822 | 1.00 | GLS (0.62) | GLSCDK5CDK2CCNE1CDK5R1 | |
| SCHEMBL17115643 | 0.95 | GLS (0.57) | GLSCDK5CDK2CCNE1CDK5R1 | |
| SCHEMBL17115632 | 0.95 | GLS (0.57) | GLSCDK5CDK2CCNE1CDK5R1 | |
| SCHEMBL18861488 | 0.95 | GLS (0.57) | GLSCDK5CDK2CCNE1CDK5R1 | |
| SCHEMBL18861552 | 0.89 | GLS (0.61) | GLSCDK5CDK2CCNE1CDK5R1 | |
| SCHEMBL18861423 | 0.89 | GLS (0.61) | GLSCDK5CDK2CCNE1CDK5R1 | |
| SCHEMBL17115638 | 0.89 | GLS (0.80) | GLSCDK5CDK2CCNE1CDK5R1 | |
| SCHEMBL17115642 | 0.89 | GLS (0.80) | GLSCDK5CDK2CCNE1CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000479-B2 | Compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-10000479-B2 | Compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170137414-A1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137414-A1 | COMPOUNDS AND THEIR METHODS OF USE | GLS, GLS2, GLUL | GLS 1/4885CDK5 1049/4885CDK2 711/4885 |
| US-10000479-B2 | Compounds and their methods of use | GLS, GLS2, GLUL | GLS 1/4885CDK5 1049/4885CDK2 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.